The effect of polymorphic genetic markers CYP2С19 (rs4244285 and rs4986893), CYP2D6 (rs3892097), ABCB1 (rs1045642) on sedation during treatment with histamine H1-receptor antagonistDownload in PDF
To study the effect of polymorphic genetic markers CYP2С19 (rs4244285 and rs4986893), CYP2D6 (rs3892097), and ABCB1 (rs1045642) on the development of sedation during treatment with histamine H 1 receptor antagonist in patients with allergic dermatitis.
Material and methods
Fifty patients with allergic dermatitis were enrolled into the clinical study. All patients were treated with loratadine 10-20 mg once daily for more than 5 days. Genotyping CYP2С19*2 and *3 (rs4244285 and rs4986893), CYP2D6*4 (rs3892097), ABCB1*6 (rs1045642) was carried out by real-time polymerase chain reaction. Safety was assessed using the targeted method of V. Tsvetov and a visual analogue scale.
In patients with GA + AA genotypes of the rs4244285 CYP2C19 polymorphic marker, sedation was more prominent (p<0.05) within 30 minutes, 2, 4, 8, 10, 12 hours after administration compared to patients with GG genotype, whereas intensity of sedation was similar in patients with the other polymorphic genetic markers.
A carriage of an allelic variant A of a polymorphic marker rs4244285 CYP2C19 gene is associated with an increased sedation during treatment with loratadine.
Pharmacogenetics, sedation, histamine H1 receptor antagonists, loratadine.